Boston Properties (BXP) has experienced an intriguing year with a mixture of highs and lows. The company's stake has been reduced by the State of New Jersey Common Pension Fund D and Andra AP fonden, but it has seen its holdings boosted by National Bank of Canada FI and Principal Financial Group Inc. It hit a 52-week high of
$75.73 and saw a price target increase to
$82.00 at Scotiabank. Although it slightly missed Q2 leasing occupancy estimates, BXP still exceeded Q2 earnings estimates. The company sold a
45% interest in Kendall Square Life Sciences Property and another interest of Cambridge Life Sciences Property. Boosts in office leasing activity have been driven primarily by East Coast markets. The company has rebranded to better reflect its
national focus, sold $850 million of senior unsecured notes, and agreed to sell a 45% interest in Kendall Square Life Sciences Properties. There have been lawsuits related to construction at Kendall Square, but the firm also signed a deal with MassDOT for Back Bay Tower Development and emerged victorious in a court ruling on building the AstraZeneca Lab Tower.
Boston Properties BXP News Analytics from Thu, 05 Mar 2020 08:00:00 GMT to Sun, 15 Sep 2024 13:04:24 GMT -
Rating 2
- Innovation -4
- Information 6
- Rumor -4
